Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARES: Durvalumab and Ablative Radiation in Extensive-Stage Small Cell Lung Cancer
NCT05068232Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- Aug 2022
- Primary completion
- Oct 2027
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in small cell lung cancer (SCLC), sponsored by University of Chicago. Started Aug 2022; status: recruiting.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05068232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05068232.